AU4714500A - Growth factor homolog zvegf4 - Google Patents

Info

Publication number

AU4714500A

AU4714500A AU47145/00A AU4714500A AU4714500A AU 4714500 A AU4714500 A AU 4714500A AU 47145/00 A AU47145/00 A AU 47145/00A AU 4714500 A AU4714500 A AU 4714500A AU 4714500 A AU4714500 A AU 4714500A

Authority

AU

Australia

Prior art keywords

seq

residues

polypeptide

zvegf4

protein

Prior art date

1999-05-03

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Abandoned

Links

• Espacenet
• Global Dossier
• Discuss

• 239000003102 growth factor Substances 0.000 title description 49
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 373
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 328
• 229920001184 polypeptide Polymers 0.000 claims description 314
• 210000004027 cell Anatomy 0.000 claims description 312
• 108090000623 proteins and genes Proteins 0.000 claims description 277
• 102000004169 proteins and genes Human genes 0.000 claims description 233
• 235000018102 proteins Nutrition 0.000 claims description 229
• 238000000034 method Methods 0.000 claims description 103
• 102000040430 polynucleotide Human genes 0.000 claims description 64
• 108091033319 polynucleotide Proteins 0.000 claims description 64
• 239000002157 polynucleotide Substances 0.000 claims description 64
• 230000014509 gene expression Effects 0.000 claims description 48
• 230000027455 binding Effects 0.000 claims description 42
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 40
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 40
• 102000005962 receptors Human genes 0.000 claims description 40
• 108020003175 receptors Proteins 0.000 claims description 40
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 35
• 235000001014 amino acid Nutrition 0.000 claims description 34
• 230000000295 complement effect Effects 0.000 claims description 25
• 230000003248 secreting effect Effects 0.000 claims description 24
• 150000001413 amino acids Chemical class 0.000 claims description 22
• 239000013604 expression vector Substances 0.000 claims description 22
• 125000000539 amino acid group Chemical group 0.000 claims description 20
• 230000012010 growth Effects 0.000 claims description 19
• 239000002773 nucleotide Substances 0.000 claims description 17
• 125000003729 nucleotide group Chemical group 0.000 claims description 17
• 238000013518 transcription Methods 0.000 claims description 17
• 230000035897 transcription Effects 0.000 claims description 17
• 210000000988 bone and bone Anatomy 0.000 claims description 16
• 230000002068 genetic effect Effects 0.000 claims description 14
• 230000035755 proliferation Effects 0.000 claims description 14
• 230000004069 differentiation Effects 0.000 claims description 13
• 108010076504 Protein Sorting Signals Proteins 0.000 claims description 12
• 239000007795 chemical reaction product Substances 0.000 claims description 12
• 238000012258 culturing Methods 0.000 claims description 11
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 10
• 230000001404 mediated effect Effects 0.000 claims description 10
• 238000013508 migration Methods 0.000 claims description 10
• 239000000047 product Substances 0.000 claims description 10
• 230000004663 cell proliferation Effects 0.000 claims description 9
• 108091008606 PDGF receptors Proteins 0.000 claims description 8
• 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 claims description 8
• 108010073925 Vascular Endothelial Growth Factor B Proteins 0.000 claims description 8
• 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 claims description 8
• 108010017843 platelet-derived growth factor A Proteins 0.000 claims description 8
• 108010073919 Vascular Endothelial Growth Factor D Proteins 0.000 claims description 7
• 230000024245 cell differentiation Effects 0.000 claims description 7
• 230000012292 cell migration Effects 0.000 claims description 7
• 210000004748 cultured cell Anatomy 0.000 claims description 7
• 230000005012 migration Effects 0.000 claims description 7
• 102100037596 Platelet-derived growth factor subunit A Human genes 0.000 claims description 6
• 210000002449 bone cell Anatomy 0.000 claims description 6
• 230000002401 inhibitory effect Effects 0.000 claims description 5
• 239000008194 pharmaceutical composition Substances 0.000 claims description 5
• 230000005856 abnormality Effects 0.000 claims description 4
• 230000033077 cellular process Effects 0.000 claims description 4
• 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims description 4
• 230000004060 metabolic process Effects 0.000 claims description 4
• 108060003951 Immunoglobulin Proteins 0.000 claims description 3
• 230000003213 activating effect Effects 0.000 claims description 3
• 230000019522 cellular metabolic process Effects 0.000 claims description 3
• 239000000710 homodimer Substances 0.000 claims description 3
• 102000018358 immunoglobulin Human genes 0.000 claims description 3
• 230000004936 stimulating effect Effects 0.000 claims description 3
• 102000001393 Platelet-Derived Growth Factor alpha Receptor Human genes 0.000 claims description 2
• 108010068588 Platelet-Derived Growth Factor alpha Receptor Proteins 0.000 claims description 2
• 230000006907 apoptotic process Effects 0.000 claims description 2
• 239000000833 heterodimer Substances 0.000 claims description 2
• 102000018967 Platelet-Derived Growth Factor beta Receptor Human genes 0.000 claims 1
• 108010051742 Platelet-Derived Growth Factor beta Receptor Proteins 0.000 claims 1
• 102000009521 Vascular Endothelial Growth Factor B Human genes 0.000 claims 1
• 102000009520 Vascular Endothelial Growth Factor C Human genes 0.000 claims 1
• 102000009519 Vascular Endothelial Growth Factor D Human genes 0.000 claims 1
• 108020004414 DNA Proteins 0.000 description 114
• 241000282414 Homo sapiens Species 0.000 description 71
• 230000000694 effects Effects 0.000 description 58
• 238000003556 assay Methods 0.000 description 52
• 239000012634 fragment Substances 0.000 description 51
• 210000001519 tissue Anatomy 0.000 description 50
• 239000000243 solution Substances 0.000 description 40
• 239000000499 gel Substances 0.000 description 38
• 108020004635 Complementary DNA Proteins 0.000 description 37
• 239000000203 mixture Substances 0.000 description 36
• 239000013598 vector Substances 0.000 description 34
• 241000699666 Mus <mouse, genus> Species 0.000 description 33
• 238000010804 cDNA synthesis Methods 0.000 description 33
• 239000002299 complementary DNA Substances 0.000 description 33
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 32
• 239000002609 medium Substances 0.000 description 32
• 238000012360 testing method Methods 0.000 description 32
• 241001465754 Metazoa Species 0.000 description 31
• 241000701161 unidentified adenovirus Species 0.000 description 30
• 238000011282 treatment Methods 0.000 description 29
• 239000013612 plasmid Substances 0.000 description 27
• 239000000523 sample Substances 0.000 description 26
• 241000699670 Mus sp. Species 0.000 description 25
• 239000005557 antagonist Substances 0.000 description 25
• 241000700605 Viruses Species 0.000 description 23
• 238000005516 engineering process Methods 0.000 description 23
• 238000004458 analytical method Methods 0.000 description 22
• 238000006243 chemical reaction Methods 0.000 description 21
• 206010052428 Wound Diseases 0.000 description 20
• 208000027418 Wounds and injury Diseases 0.000 description 20
• 238000006467 substitution reaction Methods 0.000 description 20
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
• 229940024606 amino acid Drugs 0.000 description 19
• 238000001727 in vivo Methods 0.000 description 19
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 18
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 18
• 150000001875 compounds Chemical class 0.000 description 18
• 230000004927 fusion Effects 0.000 description 18
• 238000009396 hybridization Methods 0.000 description 18
• 210000002569 neuron Anatomy 0.000 description 18
• 108020004705 Codon Proteins 0.000 description 17
• 108050003978 Semaphorin Proteins 0.000 description 17
• 238000003776 cleavage reaction Methods 0.000 description 17
• 238000010790 dilution Methods 0.000 description 17
• 239000012895 dilution Substances 0.000 description 17
• 239000012091 fetal bovine serum Substances 0.000 description 17
• 238000004519 manufacturing process Methods 0.000 description 17
• 230000007017 scission Effects 0.000 description 17
• 241000588724 Escherichia coli Species 0.000 description 16
• 102000014105 Semaphorin Human genes 0.000 description 16
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
• 239000012528 membrane Substances 0.000 description 16
• 230000004044 response Effects 0.000 description 16
• 239000011780 sodium chloride Substances 0.000 description 16
• 206010028980 Neoplasm Diseases 0.000 description 15
• 230000033115 angiogenesis Effects 0.000 description 15
• 239000003153 chemical reaction reagent Substances 0.000 description 15
• 239000003636 conditioned culture medium Substances 0.000 description 15
• 238000000338 in vitro Methods 0.000 description 15
• 210000004185 liver Anatomy 0.000 description 15
• 210000004379 membrane Anatomy 0.000 description 15
• 210000000056 organ Anatomy 0.000 description 15
• 230000009261 transgenic effect Effects 0.000 description 15
• 108091028043 Nucleic acid sequence Proteins 0.000 description 14
• 238000011161 development Methods 0.000 description 14
• 210000003668 pericyte Anatomy 0.000 description 14
• DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 14
• 230000002792 vascular Effects 0.000 description 14
• 108010000521 Human Growth Hormone Proteins 0.000 description 13
• 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 13
• 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 13
• 230000004071 biological effect Effects 0.000 description 13
• 230000015572 biosynthetic process Effects 0.000 description 13
• 230000018109 developmental process Effects 0.000 description 13
• 210000002950 fibroblast Anatomy 0.000 description 13
• 238000002347 injection Methods 0.000 description 13
• 239000007924 injection Substances 0.000 description 13
• 239000003550 marker Substances 0.000 description 13
• 230000014511 neuron projection development Effects 0.000 description 13
• 239000002953 phosphate buffered saline Substances 0.000 description 13
• 102000002265 Human Growth Hormone Human genes 0.000 description 12
• 239000000854 Human Growth Hormone Substances 0.000 description 12
• 239000000872 buffer Substances 0.000 description 12
• 201000010099 disease Diseases 0.000 description 12
• 239000003814 drug Substances 0.000 description 12
• 230000001965 increasing effect Effects 0.000 description 12
• 239000011159 matrix material Substances 0.000 description 12
• 230000008569 process Effects 0.000 description 12
• 241000894007 species Species 0.000 description 12
• 230000001225 therapeutic effect Effects 0.000 description 12
• 108010043121 Green Fluorescent Proteins Proteins 0.000 description 11
• 102000004144 Green Fluorescent Proteins Human genes 0.000 description 11
• 108010025020 Nerve Growth Factor Proteins 0.000 description 11
• 102000015336 Nerve Growth Factor Human genes 0.000 description 11
• 102000004207 Neuropilin-1 Human genes 0.000 description 11
• 108090000772 Neuropilin-1 Proteins 0.000 description 11
• 241000700159 Rattus Species 0.000 description 11
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 11
• 239000000556 agonist Substances 0.000 description 11
• 230000008859 change Effects 0.000 description 11
• 239000003795 chemical substances by application Substances 0.000 description 11
• 229960003067 cystine Drugs 0.000 description 11
• 238000009472 formulation Methods 0.000 description 11
• 239000003112 inhibitor Substances 0.000 description 11
• 239000006166 lysate Substances 0.000 description 11
• 229940053128 nerve growth factor Drugs 0.000 description 11
• 238000001890 transfection Methods 0.000 description 11
• 230000029663 wound healing Effects 0.000 description 11
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 10
• LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 10
• 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 10
• 229940079593 drug Drugs 0.000 description 10
• 235000013601 eggs Nutrition 0.000 description 10
• 210000002889 endothelial cell Anatomy 0.000 description 10
• 239000005090 green fluorescent protein Substances 0.000 description 10
• 230000005764 inhibitory process Effects 0.000 description 10
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 10
• 108020004999 messenger RNA Proteins 0.000 description 10
• 230000002297 mitogenic effect Effects 0.000 description 10
• 230000010076 replication Effects 0.000 description 10
• 238000012216 screening Methods 0.000 description 10
• 241000701447 unidentified baculovirus Species 0.000 description 10
• 241000972773 Aulopiformes Species 0.000 description 9
• 108090000790 Enzymes Proteins 0.000 description 9
• 230000004913 activation Effects 0.000 description 9
• 229940098773 bovine serum albumin Drugs 0.000 description 9
• 108020001507 fusion proteins Proteins 0.000 description 9
• 102000037865 fusion proteins Human genes 0.000 description 9
• 239000001963 growth medium Substances 0.000 description 9
• 238000010348 incorporation Methods 0.000 description 9
• 238000011534 incubation Methods 0.000 description 9
• 238000003780 insertion Methods 0.000 description 9
• 230000037431 insertion Effects 0.000 description 9
• 239000002502 liposome Substances 0.000 description 9
• 235000019515 salmon Nutrition 0.000 description 9
• 238000012546 transfer Methods 0.000 description 9
• 238000001262 western blot Methods 0.000 description 9
• HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
• 108010035532 Collagen Proteins 0.000 description 8
• 102000008186 Collagen Human genes 0.000 description 8
• 102000004190 Enzymes Human genes 0.000 description 8
• 206010016654 Fibrosis Diseases 0.000 description 8
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 8
• 206010029113 Neovascularisation Diseases 0.000 description 8
• 241000283973 Oryctolagus cuniculus Species 0.000 description 8
• 230000000692 anti-sense effect Effects 0.000 description 8
• 210000004369 blood Anatomy 0.000 description 8
• 239000008280 blood Substances 0.000 description 8
• AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 8
• 229920001436 collagen Polymers 0.000 description 8
• 238000012217 deletion Methods 0.000 description 8
• 230000037430 deletion Effects 0.000 description 8
• 229940088598 enzyme Drugs 0.000 description 8
• 210000003734 kidney Anatomy 0.000 description 8
• 210000002966 serum Anatomy 0.000 description 8
• -1 zvegf3 Proteins 0.000 description 8
• 102000004127 Cytokines Human genes 0.000 description 7
• 108090000695 Cytokines Proteins 0.000 description 7
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 7
• 238000002965 ELISA Methods 0.000 description 7
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 7
• 108010090319 Semaphorin-3A Proteins 0.000 description 7
• 239000007983 Tris buffer Substances 0.000 description 7
• 102100038217 Vascular endothelial growth factor B Human genes 0.000 description 7
• 102100038232 Vascular endothelial growth factor C Human genes 0.000 description 7
• 230000002491 angiogenic effect Effects 0.000 description 7
• 201000011510 cancer Diseases 0.000 description 7
• 230000036755 cellular response Effects 0.000 description 7
• 230000001684 chronic effect Effects 0.000 description 7
• 208000019425 cirrhosis of liver Diseases 0.000 description 7
• 238000010367 cloning Methods 0.000 description 7
• 238000007796 conventional method Methods 0.000 description 7
• 235000013861 fat-free Nutrition 0.000 description 7
• 230000003993 interaction Effects 0.000 description 7
• 210000004962 mammalian cell Anatomy 0.000 description 7
• 235000013336 milk Nutrition 0.000 description 7
• 239000008267 milk Substances 0.000 description 7
• 210000004080 milk Anatomy 0.000 description 7
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 7
• 229940054269 sodium pyruvate Drugs 0.000 description 7
• 210000004500 stellate cell Anatomy 0.000 description 7
• 239000006228 supernatant Substances 0.000 description 7
• 238000003786 synthesis reaction Methods 0.000 description 7
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 7
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
• 108091026890 Coding region Proteins 0.000 description 6
• 108010010803 Gelatin Proteins 0.000 description 6
• 241001529936 Murinae Species 0.000 description 6
• 102000002111 Neuropilin Human genes 0.000 description 6
• 108050009450 Neuropilin Proteins 0.000 description 6
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
• 102100038234 Vascular endothelial growth factor D Human genes 0.000 description 6
• 238000010171 animal model Methods 0.000 description 6
• 239000000427 antigen Substances 0.000 description 6
• 108091007433 antigens Proteins 0.000 description 6
• 102000036639 antigens Human genes 0.000 description 6
• 230000008901 benefit Effects 0.000 description 6
• 210000004899 c-terminal region Anatomy 0.000 description 6
• 210000001612 chondrocyte Anatomy 0.000 description 6
• 238000004587 chromatography analysis Methods 0.000 description 6
• 239000000539 dimer Substances 0.000 description 6
• 238000004520 electroporation Methods 0.000 description 6
• 210000003527 eukaryotic cell Anatomy 0.000 description 6
• 239000000284 extract Substances 0.000 description 6
• 238000000605 extraction Methods 0.000 description 6
• 239000008273 gelatin Substances 0.000 description 6
• 229920000159 gelatin Polymers 0.000 description 6
• 235000019322 gelatine Nutrition 0.000 description 6
• 235000011852 gelatine desserts Nutrition 0.000 description 6
• 210000002216 heart Anatomy 0.000 description 6
• 230000000302 ischemic effect Effects 0.000 description 6
• 239000003446 ligand Substances 0.000 description 6
• 150000002632 lipids Chemical class 0.000 description 6
• 229920002521 macromolecule Polymers 0.000 description 6
• 238000005259 measurement Methods 0.000 description 6
• 230000037361 pathway Effects 0.000 description 6
• 230000008488 polyadenylation Effects 0.000 description 6
• 239000002243 precursor Substances 0.000 description 6
• 230000002206 pro-fibrotic effect Effects 0.000 description 6
• 230000001737 promoting effect Effects 0.000 description 6
• 238000000746 purification Methods 0.000 description 6
• 238000011160 research Methods 0.000 description 6
• 208000037803 restenosis Diseases 0.000 description 6
• 206010039073 rheumatoid arthritis Diseases 0.000 description 6
• 210000003491 skin Anatomy 0.000 description 6
• 230000000638 stimulation Effects 0.000 description 6
• UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
• 239000000126 substance Substances 0.000 description 6
• 230000004083 survival effect Effects 0.000 description 6
• 230000008685 targeting Effects 0.000 description 6
• 238000012384 transportation and delivery Methods 0.000 description 6
• 230000003612 virological effect Effects 0.000 description 6
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
• 108091029865 Exogenous DNA Proteins 0.000 description 5
• KOSRFJWDECSPRO-WDSKDSINSA-N Glu-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(O)=O KOSRFJWDECSPRO-WDSKDSINSA-N 0.000 description 5
• 241000238631 Hexapoda Species 0.000 description 5
• 101000695352 Homo sapiens Bone morphogenetic protein 1 Proteins 0.000 description 5
• 102000004877 Insulin Human genes 0.000 description 5
• 108090001061 Insulin Proteins 0.000 description 5
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 5
• 101710094503 Metallothionein-1 Proteins 0.000 description 5
• 241000699660 Mus musculus Species 0.000 description 5
• 108091061960 Naked DNA Proteins 0.000 description 5
• 102000035195 Peptidases Human genes 0.000 description 5
• 108091005804 Peptidases Proteins 0.000 description 5
• 239000004365 Protease Substances 0.000 description 5
• 102100027974 Semaphorin-3A Human genes 0.000 description 5
• 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 5
• 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 5
• 241000269368 Xenopus laevis Species 0.000 description 5
• KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 5
• 210000000709 aorta Anatomy 0.000 description 5
• 210000001185 bone marrow Anatomy 0.000 description 5
• 229910002091 carbon monoxide Inorganic materials 0.000 description 5
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
• 210000000845 cartilage Anatomy 0.000 description 5
• 230000007882 cirrhosis Effects 0.000 description 5
• 230000000120 cytopathologic effect Effects 0.000 description 5
• 231100000433 cytotoxic Toxicity 0.000 description 5
• 230000001472 cytotoxic effect Effects 0.000 description 5
• 230000002500 effect on skin Effects 0.000 description 5
• 230000003511 endothelial effect Effects 0.000 description 5
• 230000006539 extracellular acidification Effects 0.000 description 5
• 210000003414 extremity Anatomy 0.000 description 5
• 108010055341 glutamyl-glutamic acid Proteins 0.000 description 5
• 210000003958 hematopoietic stem cell Anatomy 0.000 description 5
• 206010020718 hyperplasia Diseases 0.000 description 5
• 239000007943 implant Substances 0.000 description 5
• 208000015181 infectious disease Diseases 0.000 description 5
• 229940125396 insulin Drugs 0.000 description 5
• 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 5
• 238000011813 knockout mouse model Methods 0.000 description 5
• 210000004072 lung Anatomy 0.000 description 5
• 238000000520 microinjection Methods 0.000 description 5
• 239000000178 monomer Substances 0.000 description 5
• 238000002703 mutagenesis Methods 0.000 description 5
• 231100000350 mutagenesis Toxicity 0.000 description 5
• 230000035772 mutation Effects 0.000 description 5
• 230000001537 neural effect Effects 0.000 description 5
• 230000003472 neutralizing effect Effects 0.000 description 5
• 230000007170 pathology Effects 0.000 description 5
• 239000008188 pellet Substances 0.000 description 5
• 208000028169 periodontal disease Diseases 0.000 description 5
• 230000002829 reductive effect Effects 0.000 description 5
• 230000001105 regulatory effect Effects 0.000 description 5
• 230000008439 repair process Effects 0.000 description 5
• 210000000329 smooth muscle myocyte Anatomy 0.000 description 5
• 210000000130 stem cell Anatomy 0.000 description 5
• 238000001356 surgical procedure Methods 0.000 description 5
• 229960000187 tissue plasminogen activator Drugs 0.000 description 5
• 239000003053 toxin Substances 0.000 description 5
• 238000011830 transgenic mouse model Methods 0.000 description 5
• 230000014616 translation Effects 0.000 description 5
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
• QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
• 208000002109 Argyria Diseases 0.000 description 4
• 201000001320 Atherosclerosis Diseases 0.000 description 4
• 241000283690 Bos taurus Species 0.000 description 4
• 102000053602 DNA Human genes 0.000 description 4
• 206010012689 Diabetic retinopathy Diseases 0.000 description 4
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
• 101150021185 FGF gene Proteins 0.000 description 4
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
• 229920002683 Glycosaminoglycan Polymers 0.000 description 4
• 239000007995 HEPES buffer Substances 0.000 description 4
• 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 4
• 229930182816 L-glutamine Natural products 0.000 description 4
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 4
• CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
• 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 4
• 239000000020 Nitrocellulose Substances 0.000 description 4
• 238000000636 Northern blotting Methods 0.000 description 4
• 241001452677 Ogataea methanolica Species 0.000 description 4
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 4
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 4
• 108700008625 Reporter Genes Proteins 0.000 description 4
• 229920002684 Sepharose Polymers 0.000 description 4
• 238000012300 Sequence Analysis Methods 0.000 description 4
• IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
• 108090000631 Trypsin Proteins 0.000 description 4
• 102000004142 Trypsin Human genes 0.000 description 4
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 4
• 230000001154 acute effect Effects 0.000 description 4
• 238000007792 addition Methods 0.000 description 4
• 239000002671 adjuvant Substances 0.000 description 4
• 239000011543 agarose gel Substances 0.000 description 4
• 230000003321 amplification Effects 0.000 description 4
• 230000003171 anti-complementary effect Effects 0.000 description 4
• 210000002469 basement membrane Anatomy 0.000 description 4
• 239000011324 bead Substances 0.000 description 4
• 238000005119 centrifugation Methods 0.000 description 4
• 238000000502 dialysis Methods 0.000 description 4
• 238000006471 dimerization reaction Methods 0.000 description 4
• 208000035475 disorder Diseases 0.000 description 4
• 239000000975 dye Substances 0.000 description 4
• 210000002257 embryonic structure Anatomy 0.000 description 4
• 230000002708 enhancing effect Effects 0.000 description 4
• 238000002474 experimental method Methods 0.000 description 4
• 230000003394 haemopoietic effect Effects 0.000 description 4
• 230000035876 healing Effects 0.000 description 4
• 210000005119 human aortic smooth muscle cell Anatomy 0.000 description 4
• 208000028867 ischemia Diseases 0.000 description 4
• 210000004698 lymphocyte Anatomy 0.000 description 4
• MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 4
• 210000001616 monocyte Anatomy 0.000 description 4
• 210000002241 neurite Anatomy 0.000 description 4
• 230000007514 neuronal growth Effects 0.000 description 4
• 229920001220 nitrocellulos Polymers 0.000 description 4
• 229910052757 nitrogen Inorganic materials 0.000 description 4
• 238000003199 nucleic acid amplification method Methods 0.000 description 4
• 102000039446 nucleic acids Human genes 0.000 description 4
• 108020004707 nucleic acids Proteins 0.000 description 4
• 150000007523 nucleic acids Chemical class 0.000 description 4
• 239000002777 nucleoside Substances 0.000 description 4
• 125000003835 nucleoside group Chemical group 0.000 description 4
• 210000000963 osteoblast Anatomy 0.000 description 4
• 210000003101 oviduct Anatomy 0.000 description 4
• 239000002245 particle Substances 0.000 description 4
• 208000028591 pheochromocytoma Diseases 0.000 description 4
• 239000004417 polycarbonate Substances 0.000 description 4
• 239000013641 positive control Substances 0.000 description 4
• 208000005069 pulmonary fibrosis Diseases 0.000 description 4
• 230000009467 reduction Effects 0.000 description 4
• 108091008146 restriction endonucleases Proteins 0.000 description 4
• 230000002207 retinal effect Effects 0.000 description 4
• 239000000758 substrate Substances 0.000 description 4
• 230000009466 transformation Effects 0.000 description 4
• 230000001131 transforming effect Effects 0.000 description 4
• 239000012588 trypsin Substances 0.000 description 4
• KWVJHCQQUFDPLU-YEUCEMRASA-N 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KWVJHCQQUFDPLU-YEUCEMRASA-N 0.000 description 3
• 108020005345 3' Untranslated Regions Proteins 0.000 description 3
• AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 3
• 238000010600 3H thymidine incorporation assay Methods 0.000 description 3
• JYCQQPHGFMYQCF-UHFFFAOYSA-N 4-tert-Octylphenol monoethoxylate Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCO)C=C1 JYCQQPHGFMYQCF-UHFFFAOYSA-N 0.000 description 3
• 229920000936 Agarose Polymers 0.000 description 3
• 108010088751 Albumins Proteins 0.000 description 3
• 102000009027 Albumins Human genes 0.000 description 3
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
• 102000009840 Angiopoietins Human genes 0.000 description 3
• 108010009906 Angiopoietins Proteins 0.000 description 3
• 241000894006 Bacteria Species 0.000 description 3
• 102100028728 Bone morphogenetic protein 1 Human genes 0.000 description 3
• 241001260012 Bursa Species 0.000 description 3
• 108090000994 Catalytic RNA Proteins 0.000 description 3
• 102000053642 Catalytic RNA Human genes 0.000 description 3
• 102000000844 Cell Surface Receptors Human genes 0.000 description 3
• 108010001857 Cell Surface Receptors Proteins 0.000 description 3
• 206010069729 Collateral circulation Diseases 0.000 description 3
• 101710112752 Cytotoxin Proteins 0.000 description 3
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
• 108091060211 Expressed sequence tag Proteins 0.000 description 3
• 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 3
• 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 3
• 102100037362 Fibronectin Human genes 0.000 description 3
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
• 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
• 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 3
• 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
• 108090000157 Metallothionein Proteins 0.000 description 3
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
• 108700026244 Open Reading Frames Proteins 0.000 description 3
• 239000004743 Polypropylene Substances 0.000 description 3
• 241000256251 Spodoptera frugiperda Species 0.000 description 3
• 102000004338 Transferrin Human genes 0.000 description 3
• 108090000901 Transferrin Proteins 0.000 description 3
• 108090001012 Transforming Growth Factor beta Proteins 0.000 description 3
• 102000004887 Transforming Growth Factor beta Human genes 0.000 description 3
• 108700019146 Transgenes Proteins 0.000 description 3
• 230000002159 abnormal effect Effects 0.000 description 3
• 238000002835 absorbance Methods 0.000 description 3
• 230000001464 adherent effect Effects 0.000 description 3
• 210000000577 adipose tissue Anatomy 0.000 description 3
• 238000001042 affinity chromatography Methods 0.000 description 3
• 239000003708 ampul Substances 0.000 description 3
• 238000002399 angioplasty Methods 0.000 description 3
• 230000000890 antigenic effect Effects 0.000 description 3
• 238000013459 approach Methods 0.000 description 3
• 230000001580 bacterial effect Effects 0.000 description 3
• IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 3
• 239000012148 binding buffer Substances 0.000 description 3
• 230000000975 bioactive effect Effects 0.000 description 3
• 229960002685 biotin Drugs 0.000 description 3
• 235000020958 biotin Nutrition 0.000 description 3
• 239000011616 biotin Substances 0.000 description 3
• 238000004820 blood count Methods 0.000 description 3
• 210000004204 blood vessel Anatomy 0.000 description 3
• 230000001413 cellular effect Effects 0.000 description 3
• 230000021615 conjugation Effects 0.000 description 3
• 239000013078 crystal Substances 0.000 description 3
• 231100000599 cytotoxic agent Toxicity 0.000 description 3
• 239000002619 cytotoxin Substances 0.000 description 3
• 230000006378 damage Effects 0.000 description 3
• 239000003398 denaturant Substances 0.000 description 3
• 238000004925 denaturation Methods 0.000 description 3
• 230000036425 denaturation Effects 0.000 description 3
• 238000013461 design Methods 0.000 description 3
• 239000003623 enhancer Substances 0.000 description 3
• 235000020776 essential amino acid Nutrition 0.000 description 3
• 239000003797 essential amino acid Substances 0.000 description 3
• 230000004761 fibrosis Effects 0.000 description 3
• 238000001415 gene therapy Methods 0.000 description 3
• 239000008103 glucose Substances 0.000 description 3
• 230000002440 hepatic effect Effects 0.000 description 3
• 238000002744 homologous recombination Methods 0.000 description 3
• 230000006801 homologous recombination Effects 0.000 description 3
• 229940088597 hormone Drugs 0.000 description 3
• 239000005556 hormone Substances 0.000 description 3
• 210000003917 human chromosome Anatomy 0.000 description 3
• 229910052739 hydrogen Inorganic materials 0.000 description 3
• 230000002209 hydrophobic effect Effects 0.000 description 3
• 230000003053 immunization Effects 0.000 description 3
• 238000002372 labelling Methods 0.000 description 3
• 230000003902 lesion Effects 0.000 description 3
• 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 3
• 239000002480 mineral oil Substances 0.000 description 3
• 235000010446 mineral oil Nutrition 0.000 description 3
• 208000031225 myocardial ischemia Diseases 0.000 description 3
• 210000000653 nervous system Anatomy 0.000 description 3
• 235000015097 nutrients Nutrition 0.000 description 3
• 230000003287 optical effect Effects 0.000 description 3
• 210000001672 ovary Anatomy 0.000 description 3
• 230000002018 overexpression Effects 0.000 description 3
• 210000000496 pancreas Anatomy 0.000 description 3
• 230000036961 partial effect Effects 0.000 description 3
• 210000001322 periplasm Anatomy 0.000 description 3
• 229920002704 polyhistidine Polymers 0.000 description 3
• 229920000642 polymer Polymers 0.000 description 3
• 229920001155 polypropylene Polymers 0.000 description 3
• 230000002062 proliferating effect Effects 0.000 description 3
• 238000000159 protein binding assay Methods 0.000 description 3
• 230000005855 radiation Effects 0.000 description 3
• 230000001850 reproductive effect Effects 0.000 description 3
• 238000012552 review Methods 0.000 description 3
• 108091092562 ribozyme Proteins 0.000 description 3
• 230000028327 secretion Effects 0.000 description 3
• 238000012163 sequencing technique Methods 0.000 description 3
• 239000004017 serum-free culture medium Substances 0.000 description 3
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
• 210000000952 spleen Anatomy 0.000 description 3
• 210000002784 stomach Anatomy 0.000 description 3
• 229960005322 streptomycin Drugs 0.000 description 3
• ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 3
• 229940104230 thymidine Drugs 0.000 description 3
• 231100000765 toxin Toxicity 0.000 description 3
• 108700012359 toxins Proteins 0.000 description 3
• 239000012581 transferrin Substances 0.000 description 3
• 238000013519 translation Methods 0.000 description 3
• 238000005406 washing Methods 0.000 description 3
• 210000005253 yeast cell Anatomy 0.000 description 3
• DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 2
• PDRJLZDUOULRHE-ZETCQYMHSA-N (2s)-2-amino-3-pyridin-2-ylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=N1 PDRJLZDUOULRHE-ZETCQYMHSA-N 0.000 description 2
• DFZVZEMNPGABKO-ZETCQYMHSA-N (2s)-2-amino-3-pyridin-3-ylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=CN=C1 DFZVZEMNPGABKO-ZETCQYMHSA-N 0.000 description 2
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
• XWHHYOYVRVGJJY-QMMMGPOBSA-N 4-fluoro-L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(F)C=C1 XWHHYOYVRVGJJY-QMMMGPOBSA-N 0.000 description 2
• 108020005029 5' Flanking Region Proteins 0.000 description 2
• RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
• 208000007848 Alcoholism Diseases 0.000 description 2
• 108700028369 Alleles Proteins 0.000 description 2
• 206010002091 Anaesthesia Diseases 0.000 description 2
• 239000004475 Arginine Substances 0.000 description 2
• 206010003210 Arteriosclerosis Diseases 0.000 description 2
• 241000201370 Autographa californica nucleopolyhedrovirus Species 0.000 description 2
• 241000271566 Aves Species 0.000 description 2
• 241000283707 Capra Species 0.000 description 2
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
• 102000014914 Carrier Proteins Human genes 0.000 description 2
• 206010008909 Chronic Hepatitis Diseases 0.000 description 2
• 241000699802 Cricetulus griseus Species 0.000 description 2
• 239000004971 Cross linker Substances 0.000 description 2
• 101150074155 DHFR gene Proteins 0.000 description 2
• 241000702421 Dependoparvovirus Species 0.000 description 2
• 229920004937 Dexon® Polymers 0.000 description 2
• 229920002307 Dextran Polymers 0.000 description 2
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
• 206010059866 Drug resistance Diseases 0.000 description 2
• 102100021242 Dymeclin Human genes 0.000 description 2
• 241000196324 Embryophyta Species 0.000 description 2
• 241000991587 Enterovirus C Species 0.000 description 2
• 241000283073 Equus caballus Species 0.000 description 2
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
• 108010074860 Factor Xa Proteins 0.000 description 2
• 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 2
• 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 2
• 102000004961 Furin Human genes 0.000 description 2
• 108090001126 Furin Proteins 0.000 description 2
• 241000287828 Gallus gallus Species 0.000 description 2
• 208000022461 Glomerular disease Diseases 0.000 description 2
• 239000004471 Glycine Substances 0.000 description 2
• 206010019755 Hepatitis chronic active Diseases 0.000 description 2
• 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 2
• 102100021866 Hepatocyte growth factor Human genes 0.000 description 2
• 101001111439 Homo sapiens Beta-nerve growth factor Proteins 0.000 description 2
• 101000817629 Homo sapiens Dymeclin Proteins 0.000 description 2
• 108010003272 Hyaluronate lyase Proteins 0.000 description 2
• 102000001974 Hyaluronidases Human genes 0.000 description 2
• 206010061218 Inflammation Diseases 0.000 description 2
• 102000004889 Interleukin-6 Human genes 0.000 description 2
• 108090001005 Interleukin-6 Proteins 0.000 description 2
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
• 241000235058 Komagataella pastoris Species 0.000 description 2
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
• 108060001084 Luciferase Proteins 0.000 description 2
• 239000006137 Luria-Bertani broth Substances 0.000 description 2
• PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 2
• 102000003792 Metallothionein Human genes 0.000 description 2
• 206010027476 Metastases Diseases 0.000 description 2
• 101000581498 Methylosinus trichosporium Methanobactin mb-OB3b Proteins 0.000 description 2
• 108091092878 Microsatellite Proteins 0.000 description 2
• 206010028851 Necrosis Diseases 0.000 description 2
• PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
• 108020004485 Nonsense Codon Proteins 0.000 description 2
• 108091060545 Nonsense suppressor Proteins 0.000 description 2
• 238000009004 PCR Kit Methods 0.000 description 2
• 208000037273 Pathologic Processes Diseases 0.000 description 2
• 229930182555 Penicillin Natural products 0.000 description 2
• 102100035194 Placenta growth factor Human genes 0.000 description 2
• 239000004698 Polyethylene Substances 0.000 description 2
• 201000004681 Psoriasis Diseases 0.000 description 2
• 238000012181 QIAquick gel extraction kit Methods 0.000 description 2
• 108091034057 RNA (poly(A)) Proteins 0.000 description 2
• 108020004511 Recombinant DNA Proteins 0.000 description 2
• 206010038923 Retinopathy Diseases 0.000 description 2
• 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
• 206010039710 Scleroderma Diseases 0.000 description 2
• BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
• 102000013008 Semaphorin-3A Human genes 0.000 description 2
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
• 108700025832 Serum Response Element Proteins 0.000 description 2
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
• 206010072170 Skin wound Diseases 0.000 description 2
• 208000006011 Stroke Diseases 0.000 description 2
• 241000282887 Suidae Species 0.000 description 2
• AYFVYJQAPQTCCC-UHFFFAOYSA-N THREONINE Chemical compound CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
• 208000007536 Thrombosis Diseases 0.000 description 2
• 208000025865 Ulcer Diseases 0.000 description 2
• 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 2
• 108020005202 Viral DNA Proteins 0.000 description 2
• 241000269370 Xenopus <genus> Species 0.000 description 2
• 230000009471 action Effects 0.000 description 2
• 210000004100 adrenal gland Anatomy 0.000 description 2
• 230000004075 alteration Effects 0.000 description 2
• 229960000723 ampicillin Drugs 0.000 description 2
• AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
• 230000037005 anaesthesia Effects 0.000 description 2
• 239000002870 angiogenesis inducing agent Substances 0.000 description 2
• 238000000137 annealing Methods 0.000 description 2
• 230000002788 anti-peptide Effects 0.000 description 2
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
• 208000011775 arteriosclerosis disease Diseases 0.000 description 2
• 210000001367 artery Anatomy 0.000 description 2
• 206010003246 arthritis Diseases 0.000 description 2
• 230000004009 axon guidance Effects 0.000 description 2
• 210000003719 b-lymphocyte Anatomy 0.000 description 2
• 230000009286 beneficial effect Effects 0.000 description 2
• 108091008324 binding proteins Proteins 0.000 description 2
• 230000003115 biocidal effect Effects 0.000 description 2
• 230000000903 blocking effect Effects 0.000 description 2
• 230000008468 bone growth Effects 0.000 description 2
• 210000004271 bone marrow stromal cell Anatomy 0.000 description 2
• 239000007975 buffered saline Substances 0.000 description 2
• 239000001506 calcium phosphate Substances 0.000 description 2
• 229910000389 calcium phosphate Inorganic materials 0.000 description 2
• 235000011010 calcium phosphates Nutrition 0.000 description 2
• 239000004202 carbamide Substances 0.000 description 2
• 125000000837 carbohydrate group Chemical group 0.000 description 2
• 229910052799 carbon Inorganic materials 0.000 description 2
• 235000011089 carbon dioxide Nutrition 0.000 description 2
• 230000000747 cardiac effect Effects 0.000 description 2
• 238000004113 cell culture Methods 0.000 description 2
• 239000006285 cell suspension Substances 0.000 description 2
• 230000004640 cellular pathway Effects 0.000 description 2
• 238000007385 chemical modification Methods 0.000 description 2
• 230000003399 chemotactic effect Effects 0.000 description 2
• 210000000038 chest Anatomy 0.000 description 2
• 235000013330 chicken meat Nutrition 0.000 description 2
• 210000003711 chorioallantoic membrane Anatomy 0.000 description 2
• 230000002759 chromosomal effect Effects 0.000 description 2
• PMMYEEVYMWASQN-IMJSIDKUSA-N cis-4-Hydroxy-L-proline Chemical compound O[C@@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-IMJSIDKUSA-N 0.000 description 2
• 238000007398 colorimetric assay Methods 0.000 description 2
• 230000007748 combinatorial effect Effects 0.000 description 2
• 210000002808 connective tissue Anatomy 0.000 description 2
• 230000027326 copulation Effects 0.000 description 2
• 235000018417 cysteine Nutrition 0.000 description 2
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
• 210000000805 cytoplasm Anatomy 0.000 description 2
• 230000007812 deficiency Effects 0.000 description 2
• 230000001419 dependent effect Effects 0.000 description 2
• 238000001514 detection method Methods 0.000 description 2
• 206010012601 diabetes mellitus Diseases 0.000 description 2
• 238000003745 diagnosis Methods 0.000 description 2
• 230000000447 dimerizing effect Effects 0.000 description 2
• 230000006334 disulfide bridging Effects 0.000 description 2
• 125000002228 disulfide group Chemical group 0.000 description 2
• PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 2
• 238000001962 electrophoresis Methods 0.000 description 2
• 239000002158 endotoxin Substances 0.000 description 2
• 238000011156 evaluation Methods 0.000 description 2
• 239000013613 expression plasmid Substances 0.000 description 2
• 210000002744 extracellular matrix Anatomy 0.000 description 2
• 239000012894 fetal calf serum Substances 0.000 description 2
• MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
• MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 2
• 230000002538 fungal effect Effects 0.000 description 2
• 238000002523 gelfiltration Methods 0.000 description 2
• 238000003205 genotyping method Methods 0.000 description 2
• 239000011521 glass Substances 0.000 description 2
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
• 239000008187 granular material Substances 0.000 description 2
• 201000011066 hemangioma Diseases 0.000 description 2
• 102000046917 human NGF Human genes 0.000 description 2
• 229960002773 hyaluronidase Drugs 0.000 description 2
• 239000001257 hydrogen Substances 0.000 description 2
• 230000028993 immune response Effects 0.000 description 2
• 238000002649 immunization Methods 0.000 description 2
• 239000002596 immunotoxin Substances 0.000 description 2
• 230000001771 impaired effect Effects 0.000 description 2
• 230000004054 inflammatory process Effects 0.000 description 2
• 230000000977 initiatory effect Effects 0.000 description 2
• 230000030214 innervation Effects 0.000 description 2
• 229940100601 interleukin-6 Drugs 0.000 description 2
• 238000001990 intravenous administration Methods 0.000 description 2
• 210000004153 islets of langerhan Anatomy 0.000 description 2
• 238000002955 isolation Methods 0.000 description 2
• 229930027917 kanamycin Natural products 0.000 description 2
• 229960000318 kanamycin Drugs 0.000 description 2
• SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
• 229930182823 kanamycin A Natural products 0.000 description 2
• 210000002510 keratinocyte Anatomy 0.000 description 2
• 238000002357 laparoscopic surgery Methods 0.000 description 2
• 210000000265 leukocyte Anatomy 0.000 description 2
• 210000003041 ligament Anatomy 0.000 description 2
• 238000001638 lipofection Methods 0.000 description 2
• 210000003141 lower extremity Anatomy 0.000 description 2
• 206010025135 lupus erythematosus Diseases 0.000 description 2
• 208000002780 macular degeneration Diseases 0.000 description 2
• 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
• 235000019341 magnesium sulphate Nutrition 0.000 description 2
• 239000006249 magnetic particle Substances 0.000 description 2
• 210000003584 mesangial cell Anatomy 0.000 description 2
• 230000009401 metastasis Effects 0.000 description 2
• 229960000485 methotrexate Drugs 0.000 description 2
• 230000004048 modification Effects 0.000 description 2
• 238000012986 modification Methods 0.000 description 2
• 238000010369 molecular cloning Methods 0.000 description 2
• 230000017074 necrotic cell death Effects 0.000 description 2
• 108091027963 non-coding RNA Proteins 0.000 description 2
• 102000042567 non-coding RNA Human genes 0.000 description 2
• 230000037434 nonsense mutation Effects 0.000 description 2
• 238000011275 oncology therapy Methods 0.000 description 2
• 230000005305 organ development Effects 0.000 description 2
• 230000001717 pathogenic effect Effects 0.000 description 2
• 230000009054 pathological process Effects 0.000 description 2
• 229940049954 penicillin Drugs 0.000 description 2
• 230000007030 peptide scission Effects 0.000 description 2
• 238000010647 peptide synthesis reaction Methods 0.000 description 2
• 230000002093 peripheral effect Effects 0.000 description 2
• 238000002823 phage display Methods 0.000 description 2
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
• 229920000515 polycarbonate Polymers 0.000 description 2
• 238000003752 polymerase chain reaction Methods 0.000 description 2
• 239000002244 precipitate Substances 0.000 description 2
• 230000000644 propagated effect Effects 0.000 description 2
• 230000002797 proteolythic effect Effects 0.000 description 2
• 230000006337 proteolytic cleavage Effects 0.000 description 2
• RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
• 239000011541 reaction mixture Substances 0.000 description 2
• 238000001525 receptor binding assay Methods 0.000 description 2
• 238000011069 regeneration method Methods 0.000 description 2
• 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 2
• 230000000717 retained effect Effects 0.000 description 2
• 238000003757 reverse transcription PCR Methods 0.000 description 2
• 210000003079 salivary gland Anatomy 0.000 description 2
• 150000003839 salts Chemical class 0.000 description 2
• 239000012723 sample buffer Substances 0.000 description 2
• FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
• 229910052711 selenium Inorganic materials 0.000 description 2
• 239000011669 selenium Substances 0.000 description 2
• 230000001953 sensory effect Effects 0.000 description 2
• 238000000926 separation method Methods 0.000 description 2
• 238000002864 sequence alignment Methods 0.000 description 2
• 239000000741 silica gel Substances 0.000 description 2
• 229910002027 silica gel Inorganic materials 0.000 description 2
• 238000002741 site-directed mutagenesis Methods 0.000 description 2
• 238000001542 size-exclusion chromatography Methods 0.000 description 2
• 150000003384 small molecules Chemical class 0.000 description 2
• 239000007787 solid Substances 0.000 description 2
• 239000007790 solid phase Substances 0.000 description 2
• 230000009870 specific binding Effects 0.000 description 2
• 238000001228 spectrum Methods 0.000 description 2
• PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
• 210000003594 spinal ganglia Anatomy 0.000 description 2
• 150000003431 steroids Chemical class 0.000 description 2
• 210000002536 stromal cell Anatomy 0.000 description 2
• 238000007920 subcutaneous administration Methods 0.000 description 2
• 125000001424 substituent group Chemical group 0.000 description 2
• 210000002437 synoviocyte Anatomy 0.000 description 2
• 230000002194 synthesizing effect Effects 0.000 description 2
• 210000001550 testis Anatomy 0.000 description 2
• VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
• 210000001685 thyroid gland Anatomy 0.000 description 2
• 230000000699 topical effect Effects 0.000 description 2
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
• 210000004881 tumor cell Anatomy 0.000 description 2
• 230000004565 tumor cell growth Effects 0.000 description 2
• 231100000397 ulcer Toxicity 0.000 description 2
• VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
• 210000003556 vascular endothelial cell Anatomy 0.000 description 2
• 210000005166 vasculature Anatomy 0.000 description 2
• 230000004862 vasculogenesis Effects 0.000 description 2
• 230000000982 vasogenic effect Effects 0.000 description 2
• 239000003981 vehicle Substances 0.000 description 2
• 239000013603 viral vector Substances 0.000 description 2
• OPCHFPHZPIURNA-MFERNQICSA-N (2s)-2,5-bis(3-aminopropylamino)-n-[2-(dioctadecylamino)acetyl]pentanamide Chemical compound CCCCCCCCCCCCCCCCCCN(CC(=O)NC(=O)[C@H](CCCNCCCN)NCCCN)CCCCCCCCCCCCCCCCCC OPCHFPHZPIURNA-MFERNQICSA-N 0.000 description 1
• UJXJZOCXEZPHIE-YFKPBYRVSA-N (2s)-2-(2-hydroxyethylamino)-4-sulfanylbutanoic acid Chemical compound OCCN[C@H](C(O)=O)CCS UJXJZOCXEZPHIE-YFKPBYRVSA-N 0.000 description 1
• FQFVANSXYKWQOT-ZETCQYMHSA-N (2s)-2-azaniumyl-3-pyridin-4-ylpropanoate Chemical compound OC(=O)[C@@H](N)CC1=CC=NC=C1 FQFVANSXYKWQOT-ZETCQYMHSA-N 0.000 description 1
• FXGZFWDCXQRZKI-VKHMYHEASA-N (2s)-5-amino-2-nitramido-5-oxopentanoic acid Chemical compound NC(=O)CC[C@@H](C(O)=O)N[N+]([O-])=O FXGZFWDCXQRZKI-VKHMYHEASA-N 0.000 description 1
• CCAIIPMIAFGKSI-DMTCNVIQSA-N (2s,3r)-3-hydroxy-2-(methylazaniumyl)butanoate Chemical compound CN[C@@H]([C@@H](C)O)C(O)=O CCAIIPMIAFGKSI-DMTCNVIQSA-N 0.000 description 1
• CNPSFBUUYIVHAP-WHFBIAKZSA-N (2s,3s)-3-methylpyrrolidin-1-ium-2-carboxylate Chemical compound C[C@H]1CCN[C@@H]1C(O)=O CNPSFBUUYIVHAP-WHFBIAKZSA-N 0.000 description 1
• RINPOXNCRXGFAV-FNXAHOOKSA-N (2s,4s,5r,6r)-5-amino-2-[(2s,3r,4r,5s,6r)-5-[(2s,3r,4r,5r,6r)-3-amino-5-hydroxy-6-(hydroxymethyl)-4-[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-2-[(2r,3s,4r,5r,6r)-6-[(e)-2-amino-3-hydroxyicos-4-enoxy]-4,5-dihydroxy-2-(h Chemical compound O[C@@H]1[C@@H](O)[C@H](OCC(N)C(O)/C=C/CCCCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](N)[C@@H](O)C2)C(O)C(O)CO)C(O)=O)[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)[C@@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RINPOXNCRXGFAV-FNXAHOOKSA-N 0.000 description 1
• NMWKYTGJWUAZPZ-WWHBDHEGSA-N (4S)-4-[[(4R,7S,10S,16S,19S,25S,28S,31R)-31-[[(2S)-2-[[(1R,6R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,53S,56S,59S,62S,65S,68S,71S,76S,79S,85S)-47-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-18-(4-aminobutyl)-27,68-bis(3-amino-3-oxopropyl)-36,71,76-tribenzyl-39-(3-carbamimidamidopropyl)-24-(2-carboxyethyl)-21,56-bis(carboxymethyl)-65,85-bis[(1R)-1-hydroxyethyl]-59-(hydroxymethyl)-62,79-bis(1H-imidazol-4-ylmethyl)-9-methyl-33-(2-methylpropyl)-8,11,17,20,23,26,29,32,35,38,41,48,54,57,60,63,66,69,72,74,77,80,83,86-tetracosaoxo-30-propan-2-yl-3,4,44,45-tetrathia-7,10,16,19,22,25,28,31,34,37,40,49,55,58,61,64,67,70,73,75,78,81,84,87-tetracosazatetracyclo[40.31.14.012,16.049,53]heptaoctacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-7-(3-carbamimidamidopropyl)-25-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-28-(1H-imidazol-4-ylmethyl)-10-methyl-6,9,12,15,18,21,24,27,30-nonaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](Cc4ccccc4)NC3=O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(=O)N[C@@H](C)C(O)=O NMWKYTGJWUAZPZ-WWHBDHEGSA-N 0.000 description 1
• PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 description 1
• WUAPFZMCVAUBPE-NJFSPNSNSA-N 188Re Chemical compound [188Re] WUAPFZMCVAUBPE-NJFSPNSNSA-N 0.000 description 1
• OSBLTNPMIGYQGY-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;boric acid Chemical compound OB(O)O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O OSBLTNPMIGYQGY-UHFFFAOYSA-N 0.000 description 1
• AXAVXPMQTGXXJZ-UHFFFAOYSA-N 2-aminoacetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound NCC(O)=O.OCC(N)(CO)CO AXAVXPMQTGXXJZ-UHFFFAOYSA-N 0.000 description 1
• BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
• 101150098072 20 gene Proteins 0.000 description 1
• 108020005065 3' Flanking Region Proteins 0.000 description 1
• XEVFXAFXZZYFSX-UHFFFAOYSA-N 3-azabicyclo[2.1.1]hexane-4-carboxylic acid Chemical compound C1C2CC1(C(=O)O)NC2 XEVFXAFXZZYFSX-UHFFFAOYSA-N 0.000 description 1
• WRDABNWSWOHGMS-UHFFFAOYSA-N AEBSF hydrochloride Chemical compound Cl.NCCC1=CC=C(S(F)(=O)=O)C=C1 WRDABNWSWOHGMS-UHFFFAOYSA-N 0.000 description 1
• 108010066676 Abrin Proteins 0.000 description 1
• 241000228431 Acremonium chrysogenum Species 0.000 description 1
• 241000251468 Actinopterygii Species 0.000 description 1
• 229920001817 Agar Polymers 0.000 description 1
• 241000589156 Agrobacterium rhizogenes Species 0.000 description 1
• 206010001889 Alveolitis Diseases 0.000 description 1
• 208000024827 Alzheimer disease Diseases 0.000 description 1
• 229920000856 Amylose Polymers 0.000 description 1
• 102100022987 Angiogenin Human genes 0.000 description 1
• 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
• 108010039627 Aprotinin Proteins 0.000 description 1
• 208000033116 Asbestos intoxication Diseases 0.000 description 1
• 241000228212 Aspergillus Species 0.000 description 1
• 208000023275 Autoimmune disease Diseases 0.000 description 1
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
• 241000193830 Bacillus <bacterium> Species 0.000 description 1
• 231100000699 Bacterial toxin Toxicity 0.000 description 1
• 108010081589 Becaplermin Proteins 0.000 description 1
• DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
• 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
• 206010004659 Biliary cirrhosis Diseases 0.000 description 1
• 101000897479 Bos taurus C-C motif chemokine 2 Proteins 0.000 description 1
• 101000701908 Bos taurus Spermadhesin-1 Proteins 0.000 description 1
• 208000007257 Budd-Chiari syndrome Diseases 0.000 description 1
• 101710115734 CUB domain-containing protein Proteins 0.000 description 1
• 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• 241000222128 Candida maltosa Species 0.000 description 1
• 241000282465 Canis Species 0.000 description 1
• 241000282472 Canis lupus familiaris Species 0.000 description 1
• 235000002566 Capsicum Nutrition 0.000 description 1
• 208000024172 Cardiovascular disease Diseases 0.000 description 1
• 108010078791 Carrier Proteins Proteins 0.000 description 1
• 241000700198 Cavia Species 0.000 description 1
• 241000700199 Cavia porcellus Species 0.000 description 1
• 206010008120 Cerebral ischaemia Diseases 0.000 description 1
• 108010062540 Chorionic Gonadotropin Proteins 0.000 description 1
• 102000011022 Chorionic Gonadotropin Human genes 0.000 description 1
• 208000031404 Chromosome Aberrations Diseases 0.000 description 1
• 208000017667 Chronic Disease Diseases 0.000 description 1
• 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
• 101100007328 Cocos nucifera COS-1 gene Proteins 0.000 description 1
• 102000012422 Collagen Type I Human genes 0.000 description 1
• 108010022452 Collagen Type I Proteins 0.000 description 1
• 208000029147 Collagen-vascular disease Diseases 0.000 description 1
• 102000029816 Collagenase Human genes 0.000 description 1
• 108060005980 Collagenase Proteins 0.000 description 1
• 206010055665 Corneal neovascularisation Diseases 0.000 description 1
• 241000557626 Corvus corax Species 0.000 description 1
• 241000334119 Coturnix japonica Species 0.000 description 1
• 206010063075 Cryptogenic cirrhosis Diseases 0.000 description 1
• XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 1
• 241000701022 Cytomegalovirus Species 0.000 description 1
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
• 238000001712 DNA sequencing Methods 0.000 description 1
• 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
• 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
• 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
• 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
• 101710088194 Dehydrogenase Proteins 0.000 description 1
• BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
• 108090000204 Dipeptidase 1 Proteins 0.000 description 1
• 102000016607 Diphtheria Toxin Human genes 0.000 description 1
• 108010053187 Diphtheria Toxin Proteins 0.000 description 1
• 241000710188 Encephalomyocarditis virus Species 0.000 description 1
• 102400001368 Epidermal growth factor Human genes 0.000 description 1
• 101800003838 Epidermal growth factor Proteins 0.000 description 1
• YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
• 241000283086 Equidae Species 0.000 description 1
• 206010063560 Excessive granulation tissue Diseases 0.000 description 1
• 241000282324 Felis Species 0.000 description 1
• 108010067306 Fibronectins Proteins 0.000 description 1
• 206010061459 Gastrointestinal ulcer Diseases 0.000 description 1
• 102000013382 Gelatinases Human genes 0.000 description 1
• 108010026132 Gelatinases Proteins 0.000 description 1
• 206010064571 Gene mutation Diseases 0.000 description 1
• 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
• 206010018364 Glomerulonephritis Diseases 0.000 description 1
• 108010053070 Glutathione Disulfide Proteins 0.000 description 1
• 102000005720 Glutathione transferase Human genes 0.000 description 1
• 108010070675 Glutathione transferase Proteins 0.000 description 1
• 102000003886 Glycoproteins Human genes 0.000 description 1
• 108090000288 Glycoproteins Proteins 0.000 description 1
• 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
• 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
• 206010019196 Head injury Diseases 0.000 description 1
• 206010019280 Heart failures Diseases 0.000 description 1
• 206010019663 Hepatic failure Diseases 0.000 description 1
• 206010019713 Hepatic vein thrombosis Diseases 0.000 description 1
• 208000005176 Hepatitis C Diseases 0.000 description 1
• 206010019799 Hepatitis viral Diseases 0.000 description 1
• 208000002972 Hepatolenticular Degeneration Diseases 0.000 description 1
• 241000282412 Homo Species 0.000 description 1
• 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
• 101001001487 Homo sapiens Phosphatidylinositol-glycan biosynthesis class F protein Proteins 0.000 description 1
• 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 description 1
• YZJSUQQZGCHHNQ-UHFFFAOYSA-N Homoglutamine Chemical compound OC(=O)C(N)CCCC(N)=O YZJSUQQZGCHHNQ-UHFFFAOYSA-N 0.000 description 1
• PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
• 206010062767 Hypophysitis Diseases 0.000 description 1
• 206010021143 Hypoxia Diseases 0.000 description 1
• 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
• 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
• 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
• 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
• 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
• 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
• 206010062016 Immunosuppression Diseases 0.000 description 1
• 208000026350 Inborn Genetic disease Diseases 0.000 description 1
• 206010061216 Infarction Diseases 0.000 description 1
• 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
• 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
• 102100020873 Interleukin-2 Human genes 0.000 description 1
• 108010002350 Interleukin-2 Proteins 0.000 description 1
• 108010002386 Interleukin-3 Proteins 0.000 description 1
• 102000000646 Interleukin-3 Human genes 0.000 description 1
• 108090001007 Interleukin-8 Proteins 0.000 description 1
• 206010060820 Joint injury Diseases 0.000 description 1
• 206010023421 Kidney fibrosis Diseases 0.000 description 1
• 244000285963 Kluyveromyces fragilis Species 0.000 description 1
• 235000014663 Kluyveromyces fragilis Nutrition 0.000 description 1
• 241001138401 Kluyveromyces lactis Species 0.000 description 1
• SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
• SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
• HXEACLLIILLPRG-YFKPBYRVSA-N L-pipecolic acid Chemical compound [O-]C(=O)[C@@H]1CCCC[NH2+]1 HXEACLLIILLPRG-YFKPBYRVSA-N 0.000 description 1
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
• 108010085895 Laminin Proteins 0.000 description 1
• 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
• 241000270322 Lepidosauria Species 0.000 description 1
• GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
• 208000006552 Lewis Lung Carcinoma Diseases 0.000 description 1
• 108090000364 Ligases Proteins 0.000 description 1
• 102000003960 Ligases Human genes 0.000 description 1
• 108010031801 Lipopolysaccharide Receptors Proteins 0.000 description 1
• 102000005482 Lipopolysaccharide Receptors Human genes 0.000 description 1
• 206010067125 Liver injury Diseases 0.000 description 1
• 239000005089 Luciferase Substances 0.000 description 1
• 241000124008 Mammalia Species 0.000 description 1
• 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
• 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
• 108010006035 Metalloproteases Proteins 0.000 description 1
• 102000005741 Metalloproteases Human genes 0.000 description 1
• 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 1
• 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
• 101000966481 Mus musculus Dihydrofolate reductase Proteins 0.000 description 1
• 101000969137 Mus musculus Metallothionein-1 Proteins 0.000 description 1
• 101000836210 Mus musculus Somatotropin Proteins 0.000 description 1
• 241000699667 Mus spretus Species 0.000 description 1
• 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
• 229930193140 Neomycin Natural products 0.000 description 1
• 208000028389 Nerve injury Diseases 0.000 description 1
• 241000221960 Neurospora Species 0.000 description 1
• 241000320412 Ogataea angusta Species 0.000 description 1
• 102000004067 Osteocalcin Human genes 0.000 description 1
• 108090000573 Osteocalcin Proteins 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 239000002033 PVDF binder Substances 0.000 description 1
• 241001111421 Pannus Species 0.000 description 1
• 241001504519 Papio ursinus Species 0.000 description 1
• 206010033799 Paralysis Diseases 0.000 description 1
• 208000018737 Parkinson disease Diseases 0.000 description 1
• 208000034038 Pathologic Neovascularization Diseases 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 208000000450 Pelvic Pain Diseases 0.000 description 1
• 206010034238 Pelvic adhesions Diseases 0.000 description 1
• 240000007711 Peperomia pellucida Species 0.000 description 1
• 239000006002 Pepper Substances 0.000 description 1
• 108010067902 Peptide Library Proteins 0.000 description 1
• 206010034576 Peripheral ischaemia Diseases 0.000 description 1
• 208000018262 Peripheral vascular disease Diseases 0.000 description 1
• 208000031848 Peritonitis sclerosing Diseases 0.000 description 1
• 241000286209 Phasianidae Species 0.000 description 1
• BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
• 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 1
• OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
• 241000235648 Pichia Species 0.000 description 1
• 235000016761 Piper aduncum Nutrition 0.000 description 1
• 235000017804 Piper guineense Nutrition 0.000 description 1
• 244000203593 Piper nigrum Species 0.000 description 1
• 235000008184 Piper nigrum Nutrition 0.000 description 1
• 108010082093 Placenta Growth Factor Proteins 0.000 description 1
• 206010035138 Placental insufficiency Diseases 0.000 description 1
• 231100000742 Plant toxin Toxicity 0.000 description 1
• 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 1
• 229920001213 Polysorbate 20 Polymers 0.000 description 1
• 239000004793 Polystyrene Substances 0.000 description 1
• 201000009454 Portal vein thrombosis Diseases 0.000 description 1
• 108010050808 Procollagen Proteins 0.000 description 1
• 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
• 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
• 101000762949 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Exotoxin A Proteins 0.000 description 1
• LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
• 230000004570 RNA-binding Effects 0.000 description 1
• 239000012980 RPMI-1640 medium Substances 0.000 description 1
• 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 description 1
• 101000852966 Rattus norvegicus Interleukin-1 receptor-like 1 Proteins 0.000 description 1
• 208000020207 Reproductive tract disease Diseases 0.000 description 1
• 201000007981 Reye syndrome Diseases 0.000 description 1
• 108091028664 Ribonucleotide Proteins 0.000 description 1
• 108010039491 Ricin Proteins 0.000 description 1
• 241000283984 Rodentia Species 0.000 description 1
• 108010084592 Saporins Proteins 0.000 description 1
• 108010077895 Sarcosine Proteins 0.000 description 1
• 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
• 208000034189 Sclerosis Diseases 0.000 description 1
• 108010064603 Seminal Plasma Proteins Proteins 0.000 description 1
• 102000015338 Seminal Plasma Proteins Human genes 0.000 description 1
• 108091081021 Sense strand Proteins 0.000 description 1
• 229920005654 Sephadex Polymers 0.000 description 1
• XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
• 201000010001 Silicosis Diseases 0.000 description 1
• 206010041101 Small intestinal obstruction Diseases 0.000 description 1
• 238000002105 Southern blotting Methods 0.000 description 1
• 208000020339 Spinal injury Diseases 0.000 description 1
• 108010090804 Streptavidin Proteins 0.000 description 1
• 206010042573 Superovulation Diseases 0.000 description 1
• 108010008038 Synthetic Vaccines Proteins 0.000 description 1
• 208000025317 T-cell and NK-cell neoplasm Diseases 0.000 description 1
• 206010042971 T-cell lymphoma Diseases 0.000 description 1
• 210000001744 T-lymphocyte Anatomy 0.000 description 1
• 239000008049 TAE buffer Substances 0.000 description 1
• 239000008051 TBE buffer Substances 0.000 description 1
• 239000004098 Tetracycline Substances 0.000 description 1
• 102000002933 Thioredoxin Human genes 0.000 description 1
• 108091036066 Three prime untranslated region Proteins 0.000 description 1
• 108010022394 Threonine synthase Proteins 0.000 description 1
• 108090000190 Thrombin Proteins 0.000 description 1
• 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
• 108020004566 Transfer RNA Proteins 0.000 description 1
• 102400001320 Transforming growth factor alpha Human genes 0.000 description 1
• 101800004564 Transforming growth factor alpha Proteins 0.000 description 1
• 241000255993 Trichoplusia ni Species 0.000 description 1
• DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
• 229920004890 Triton X-100 Polymers 0.000 description 1
• 239000013504 Triton X-100 Substances 0.000 description 1
• 108090000848 Ubiquitin Proteins 0.000 description 1
• 102000044159 Ubiquitin Human genes 0.000 description 1
• 108091023045 Untranslated Region Proteins 0.000 description 1
• 244000301083 Ustilago maydis Species 0.000 description 1
• 235000015919 Ustilago maydis Nutrition 0.000 description 1
• 241000700618 Vaccinia virus Species 0.000 description 1
• 208000000558 Varicose Ulcer Diseases 0.000 description 1
• 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
• 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 1
• 102100039037 Vascular endothelial growth factor A Human genes 0.000 description 1
• 108700005077 Viral Genes Proteins 0.000 description 1
• 108010031318 Vitronectin Proteins 0.000 description 1
• 102100035140 Vitronectin Human genes 0.000 description 1
• 208000018839 Wilson disease Diseases 0.000 description 1
• VWQVUPCCIRVNHF-OUBTZVSYSA-N Yttrium-90 Chemical compound [90Y] VWQVUPCCIRVNHF-OUBTZVSYSA-N 0.000 description 1
• JRMSLDWZFJZLAS-UHFFFAOYSA-M [7-(dimethylamino)-1,9-dimethylphenothiazin-3-ylidene]-dimethylazanium;chloride Chemical compound [Cl-].CC1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC(C)=C3N=C21 JRMSLDWZFJZLAS-UHFFFAOYSA-M 0.000 description 1
• 210000001015 abdomen Anatomy 0.000 description 1
• 230000003187 abdominal effect Effects 0.000 description 1
• 238000002679 ablation Methods 0.000 description 1
• 206010000269 abscess Diseases 0.000 description 1
• 239000008351 acetate buffer Substances 0.000 description 1
• HGEVZDLYZYVYHD-UHFFFAOYSA-N acetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound CC(O)=O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O HGEVZDLYZYVYHD-UHFFFAOYSA-N 0.000 description 1
• 102000005421 acetyltransferase Human genes 0.000 description 1
• 108020002494 acetyltransferase Proteins 0.000 description 1
• 239000002253 acid Substances 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 208000005652 acute fatty liver of pregnancy Diseases 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 239000000853 adhesive Substances 0.000 description 1
• 230000001070 adhesive effect Effects 0.000 description 1
• 229940009456 adriamycin Drugs 0.000 description 1
• 230000002411 adverse Effects 0.000 description 1
• 238000005273 aeration Methods 0.000 description 1
• 238000001261 affinity purification Methods 0.000 description 1
• 239000008272 agar Substances 0.000 description 1
• 238000000246 agarose gel electrophoresis Methods 0.000 description 1
• 206010064930 age-related macular degeneration Diseases 0.000 description 1
• 230000002776 aggregation Effects 0.000 description 1
• 238000004220 aggregation Methods 0.000 description 1
• 235000004279 alanine Nutrition 0.000 description 1
• 238000012867 alanine scanning Methods 0.000 description 1
• 206010001584 alcohol abuse Diseases 0.000 description 1
• 201000007930 alcohol dependence Diseases 0.000 description 1
• 208000025746 alcohol use disease Diseases 0.000 description 1
• 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 description 1
• 229940037003 alum Drugs 0.000 description 1
• WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
• ROLZYTOAMYXLMF-UHFFFAOYSA-N amino(benzyl)carbamic acid Chemical compound OC(=O)N(N)CC1=CC=CC=C1 ROLZYTOAMYXLMF-UHFFFAOYSA-N 0.000 description 1
• 230000000689 aminoacylating effect Effects 0.000 description 1
• 238000012197 amplification kit Methods 0.000 description 1
• 230000000202 analgesic effect Effects 0.000 description 1
• 210000003484 anatomy Anatomy 0.000 description 1
• 208000036878 aneuploidy Diseases 0.000 description 1
• 231100001075 aneuploidy Toxicity 0.000 description 1
• 108010072788 angiogenin Proteins 0.000 description 1
• 230000001772 anti-angiogenic effect Effects 0.000 description 1
• 230000001093 anti-cancer Effects 0.000 description 1
• 230000002391 anti-complement effect Effects 0.000 description 1
• 230000003510 anti-fibrotic effect Effects 0.000 description 1
• 108010008730 anticomplement Proteins 0.000 description 1
• 239000000074 antisense oligonucleotide Substances 0.000 description 1
• 238000012230 antisense oligonucleotides Methods 0.000 description 1
• 210000002376 aorta thoracic Anatomy 0.000 description 1
• 229960004405 aprotinin Drugs 0.000 description 1
• 239000006286 aqueous extract Substances 0.000 description 1
• 239000008346 aqueous phase Substances 0.000 description 1
• 239000003125 aqueous solvent Substances 0.000 description 1
• 206010003441 asbestosis Diseases 0.000 description 1
• 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
• 235000003704 aspartic acid Nutrition 0.000 description 1
• 210000001130 astrocyte Anatomy 0.000 description 1
• 238000000376 autoradiography Methods 0.000 description 1
• 230000028600 axonogenesis Effects 0.000 description 1
• 239000000688 bacterial toxin Substances 0.000 description 1
• 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
• 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 238000001574 biopsy Methods 0.000 description 1
• 239000007844 bleaching agent Substances 0.000 description 1
• 230000000740 bleeding effect Effects 0.000 description 1
• 239000001045 blue dye Substances 0.000 description 1
• 210000001124 body fluid Anatomy 0.000 description 1
• 239000010839 body fluid Substances 0.000 description 1
• 230000037396 body weight Effects 0.000 description 1
• 238000006664 bond formation reaction Methods 0.000 description 1
• 201000006491 bone marrow cancer Diseases 0.000 description 1
• 239000005388 borosilicate glass Substances 0.000 description 1
• 210000004556 brain Anatomy 0.000 description 1
• 230000006931 brain damage Effects 0.000 description 1
• 231100000874 brain damage Toxicity 0.000 description 1
• 208000029028 brain injury Diseases 0.000 description 1
• 210000005013 brain tissue Anatomy 0.000 description 1
• 239000006172 buffering agent Substances 0.000 description 1
• 244000309464 bull Species 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
• 238000004422 calculation algorithm Methods 0.000 description 1
• 238000004364 calculation method Methods 0.000 description 1
• 238000011088 calibration curve Methods 0.000 description 1
• 230000005907 cancer growth Effects 0.000 description 1
• 229940041514 candida albicans extract Drugs 0.000 description 1
• 210000001043 capillary endothelial cell Anatomy 0.000 description 1
• 208000001969 capillary hemangioma Diseases 0.000 description 1
• 150000001720 carbohydrates Chemical class 0.000 description 1
• 235000014633 carbohydrates Nutrition 0.000 description 1
• 230000008209 cardiovascular development Effects 0.000 description 1
• 210000000748 cardiovascular system Anatomy 0.000 description 1
• 230000022159 cartilage development Effects 0.000 description 1
• 230000015556 catabolic process Effects 0.000 description 1
• 125000002091 cationic group Chemical group 0.000 description 1
• 230000021164 cell adhesion Effects 0.000 description 1
• 238000000423 cell based assay Methods 0.000 description 1
• 239000006143 cell culture medium Substances 0.000 description 1
• 230000022131 cell cycle Effects 0.000 description 1
• 230000030833 cell death Effects 0.000 description 1
• 230000032823 cell division Effects 0.000 description 1
• 230000007910 cell fusion Effects 0.000 description 1
• 230000010261 cell growth Effects 0.000 description 1
• 230000006727 cell loss Effects 0.000 description 1
• 210000000170 cell membrane Anatomy 0.000 description 1
• 239000013553 cell monolayer Substances 0.000 description 1
• 210000004671 cell-free system Anatomy 0.000 description 1
• 108091008394 cellulose binding proteins Proteins 0.000 description 1
• 210000003169 central nervous system Anatomy 0.000 description 1
• 239000003638 chemical reducing agent Substances 0.000 description 1
• YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 1
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
• 239000012501 chromatography medium Substances 0.000 description 1
• 231100000005 chromosome aberration Toxicity 0.000 description 1
• 230000014107 chromosome localization Effects 0.000 description 1
• 238000012411 cloning technique Methods 0.000 description 1
• 230000004186 co-expression Effects 0.000 description 1
• GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
• 239000000512 collagen gel Substances 0.000 description 1
• 229940096422 collagen type i Drugs 0.000 description 1
• 229960002424 collagenase Drugs 0.000 description 1
• 230000006467 collateral growth Effects 0.000 description 1
• 230000005757 colony formation Effects 0.000 description 1
• 239000002131 composite material Substances 0.000 description 1
• 230000001010 compromised effect Effects 0.000 description 1
• 238000005094 computer simulation Methods 0.000 description 1
• 239000012141 concentrate Substances 0.000 description 1
• 238000009833 condensation Methods 0.000 description 1
• 230000005494 condensation Effects 0.000 description 1
• 230000001143 conditioned effect Effects 0.000 description 1
• 208000018631 connective tissue disease Diseases 0.000 description 1
• 230000008602 contraction Effects 0.000 description 1
• 239000002872 contrast media Substances 0.000 description 1
• 230000001276 controlling effect Effects 0.000 description 1
• 210000004087 cornea Anatomy 0.000 description 1
• 201000000159 corneal neovascularization Diseases 0.000 description 1
• 230000008878 coupling Effects 0.000 description 1
• 238000010168 coupling process Methods 0.000 description 1
• 238000005859 coupling reaction Methods 0.000 description 1
• 239000013632 covalent dimer Substances 0.000 description 1
• 230000009089 cytolysis Effects 0.000 description 1
• 231100000135 cytotoxicity Toxicity 0.000 description 1
• 230000003013 cytotoxicity Effects 0.000 description 1
• 230000003247 decreasing effect Effects 0.000 description 1
• 210000004443 dendritic cell Anatomy 0.000 description 1
• 239000005547 deoxyribonucleotide Substances 0.000 description 1
• 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
• 230000008021 deposition Effects 0.000 description 1
• 210000004207 dermis Anatomy 0.000 description 1
• 239000003599 detergent Substances 0.000 description 1
• 230000001627 detrimental effect Effects 0.000 description 1
• 239000008121 dextrose Substances 0.000 description 1
• 239000000032 diagnostic agent Substances 0.000 description 1
• 229940039227 diagnostic agent Drugs 0.000 description 1
• 230000029087 digestion Effects 0.000 description 1
• 102000004419 dihydrofolate reductase Human genes 0.000 description 1
• 238000007865 diluting Methods 0.000 description 1
• MWRBNPKJOOWZPW-CLFAGFIQSA-N dioleoyl phosphatidylethanolamine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-CLFAGFIQSA-N 0.000 description 1
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
• 239000012153 distilled water Substances 0.000 description 1
• 238000009826 distribution Methods 0.000 description 1
• 208000000718 duodenal ulcer Diseases 0.000 description 1
• 239000012149 elution buffer Substances 0.000 description 1
• 230000013020 embryo development Effects 0.000 description 1
• 238000013171 endarterectomy Methods 0.000 description 1
• 230000002124 endocrine Effects 0.000 description 1
• 230000002346 endotoxic effect Effects 0.000 description 1
• 230000007613 environmental effect Effects 0.000 description 1
• 230000002255 enzymatic effect Effects 0.000 description 1
• 229940116977 epidermal growth factor Drugs 0.000 description 1
• 210000002615 epidermis Anatomy 0.000 description 1
• 210000003743 erythrocyte Anatomy 0.000 description 1
• 235000020774 essential nutrients Nutrition 0.000 description 1
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
• 238000001704 evaporation Methods 0.000 description 1
• 230000008020 evaporation Effects 0.000 description 1
• 230000003090 exacerbative effect Effects 0.000 description 1
• 238000002270 exclusion chromatography Methods 0.000 description 1
• 230000029142 excretion Effects 0.000 description 1
• 229920000295 expanded polytetrafluoroethylene Polymers 0.000 description 1
• 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 1
• 208000003816 familial cirrhosis Diseases 0.000 description 1
• 210000005002 female reproductive tract Anatomy 0.000 description 1
• 230000001605 fetal effect Effects 0.000 description 1
• 102000013361 fetuin Human genes 0.000 description 1
• 108060002885 fetuin Proteins 0.000 description 1
• 230000003176 fibrotic effect Effects 0.000 description 1
• 238000001914 filtration Methods 0.000 description 1
• 235000019688 fish Nutrition 0.000 description 1
• 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
• 238000005194 fractionation Methods 0.000 description 1
• 238000013467 fragmentation Methods 0.000 description 1
• 238000006062 fragmentation reaction Methods 0.000 description 1
• 208000020217 fulminant viral hepatitis Diseases 0.000 description 1
• 230000005714 functional activity Effects 0.000 description 1
• 210000001035 gastrointestinal tract Anatomy 0.000 description 1
• 238000001502 gel electrophoresis Methods 0.000 description 1
• 239000003349 gelling agent Substances 0.000 description 1
• 238000012224 gene deletion Methods 0.000 description 1
• 238000001476 gene delivery Methods 0.000 description 1
• 208000016361 genetic disease Diseases 0.000 description 1
• 238000012254 genetic linkage analysis Methods 0.000 description 1
• YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 1
• 230000002414 glycolytic effect Effects 0.000 description 1
• 210000001126 granulation tissue Anatomy 0.000 description 1
• 210000000020 growth cone Anatomy 0.000 description 1
• 230000009036 growth inhibition Effects 0.000 description 1
• 229960004198 guanidine Drugs 0.000 description 1
• YQOKLYTXVFAUCW-UHFFFAOYSA-N guanidine;isothiocyanic acid Chemical compound N=C=S.NC(N)=N YQOKLYTXVFAUCW-UHFFFAOYSA-N 0.000 description 1
• PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
• BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
• 229960003132 halothane Drugs 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 230000009067 heart development Effects 0.000 description 1
• 238000010438 heat treatment Methods 0.000 description 1
• 210000003566 hemangioblast Anatomy 0.000 description 1
• 201000005787 hematologic cancer Diseases 0.000 description 1
• 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
• 230000011132 hemopoiesis Effects 0.000 description 1
• 230000002008 hemorrhagic effect Effects 0.000 description 1
• 231100000234 hepatic damage Toxicity 0.000 description 1
• 210000004024 hepatic stellate cell Anatomy 0.000 description 1
• 208000002672 hepatitis B Diseases 0.000 description 1
• 210000003494 hepatocyte Anatomy 0.000 description 1
• 238000013537 high throughput screening Methods 0.000 description 1
• 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
• 230000002962 histologic effect Effects 0.000 description 1
• 229940084986 human chorionic gonadotropin Drugs 0.000 description 1
• 210000004408 hybridoma Anatomy 0.000 description 1
• 125000001165 hydrophobic group Chemical group 0.000 description 1
• MWFRVMDVLYIXJF-BYPYZUCNSA-N hydroxyethylcysteine Chemical compound OC(=O)[C@@H](N)CSCCO MWFRVMDVLYIXJF-BYPYZUCNSA-N 0.000 description 1
• 230000002390 hyperplastic effect Effects 0.000 description 1
• 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 1
• 230000002218 hypoglycaemic effect Effects 0.000 description 1
• 230000007954 hypoxia Effects 0.000 description 1
• 238000003384 imaging method Methods 0.000 description 1
• 230000008105 immune reaction Effects 0.000 description 1
• 229940127121 immunoconjugate Drugs 0.000 description 1
• 238000000760 immunoelectrophoresis Methods 0.000 description 1
• 230000005847 immunogenicity Effects 0.000 description 1
• 238000010324 immunological assay Methods 0.000 description 1
• 238000001114 immunoprecipitation Methods 0.000 description 1
• 230000001506 immunosuppresive effect Effects 0.000 description 1
• 230000006872 improvement Effects 0.000 description 1
• 238000000099 in vitro assay Methods 0.000 description 1
• 238000005462 in vivo assay Methods 0.000 description 1
• 230000006698 induction Effects 0.000 description 1
• 239000003317 industrial substance Substances 0.000 description 1
• 230000007574 infarction Effects 0.000 description 1
• 239000012678 infectious agent Substances 0.000 description 1
• 230000002458 infectious effect Effects 0.000 description 1
• 208000027866 inflammatory disease Diseases 0.000 description 1
• 230000002757 inflammatory effect Effects 0.000 description 1
• 230000028709 inflammatory response Effects 0.000 description 1
• 230000004941 influx Effects 0.000 description 1
• 238000001802 infusion Methods 0.000 description 1
• ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
• 238000011081 inoculation Methods 0.000 description 1
• 229910052500 inorganic mineral Inorganic materials 0.000 description 1
• 230000010354 integration Effects 0.000 description 1
• 230000002452 interceptive effect Effects 0.000 description 1
• 239000000543 intermediate Substances 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• 239000007928 intraperitoneal injection Substances 0.000 description 1
• 238000010253 intravenous injection Methods 0.000 description 1
• 108091005979 iodinated proteins Proteins 0.000 description 1
• 230000037427 ion transport Effects 0.000 description 1
• 230000005865 ionizing radiation Effects 0.000 description 1
• GKOZUEZYRPOHIO-IGMARMGPSA-N iridium-192 Chemical compound [192Ir] GKOZUEZYRPOHIO-IGMARMGPSA-N 0.000 description 1
• 230000002427 irreversible effect Effects 0.000 description 1
• 208000037906 ischaemic injury Diseases 0.000 description 1
• 230000002147 killing effect Effects 0.000 description 1
• 210000003127 knee Anatomy 0.000 description 1
• 210000001865 kupffer cell Anatomy 0.000 description 1
• HXEACLLIILLPRG-RXMQYKEDSA-N l-pipecolic acid Natural products OC(=O)[C@H]1CCCCN1 HXEACLLIILLPRG-RXMQYKEDSA-N 0.000 description 1
• 238000012332 laboratory investigation Methods 0.000 description 1
• 101150066555 lacZ gene Proteins 0.000 description 1
• GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
• 108010052968 leupeptin Proteins 0.000 description 1
• 230000006517 limb development Effects 0.000 description 1
• 201000002818 limb ischemia Diseases 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 239000007788 liquid Substances 0.000 description 1
• 238000009630 liquid culture Methods 0.000 description 1
• 210000005229 liver cell Anatomy 0.000 description 1
• 231100000832 liver cell necrosis Toxicity 0.000 description 1
• 230000008818 liver damage Effects 0.000 description 1
• 208000019423 liver disease Diseases 0.000 description 1
• 231100000835 liver failure Toxicity 0.000 description 1
• 208000007903 liver failure Diseases 0.000 description 1
• 210000005228 liver tissue Anatomy 0.000 description 1
• 210000005265 lung cell Anatomy 0.000 description 1
• 210000003563 lymphoid tissue Anatomy 0.000 description 1
• 230000002934 lysing effect Effects 0.000 description 1
• 239000012139 lysis buffer Substances 0.000 description 1
• 210000002540 macrophage Anatomy 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• 230000003211 malignant effect Effects 0.000 description 1
• 210000001161 mammalian embryo Anatomy 0.000 description 1
• 238000013507 mapping Methods 0.000 description 1
• 230000013011 mating Effects 0.000 description 1
• 238000002844 melting Methods 0.000 description 1
• 230000008018 melting Effects 0.000 description 1
• 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 230000001394 metastastic effect Effects 0.000 description 1
• 206010061289 metastatic neoplasm Diseases 0.000 description 1
• 229930182817 methionine Natural products 0.000 description 1
• CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 1
• 229920000609 methyl cellulose Polymers 0.000 description 1
• 239000001923 methylcellulose Substances 0.000 description 1
• 210000004925 microvascular endothelial cell Anatomy 0.000 description 1
• 210000004088 microvessel Anatomy 0.000 description 1
• 230000003278 mimic effect Effects 0.000 description 1
• 239000011707 mineral Substances 0.000 description 1
• 235000010755 mineral Nutrition 0.000 description 1
• 238000012544 monitoring process Methods 0.000 description 1
• 239000002899 monoamine oxidase inhibitor Substances 0.000 description 1
• 230000001002 morphogenetic effect Effects 0.000 description 1
• 230000004660 morphological change Effects 0.000 description 1
• 230000036457 multidrug resistance Effects 0.000 description 1
• 201000006417 multiple sclerosis Diseases 0.000 description 1
• 210000003205 muscle Anatomy 0.000 description 1
• 230000002107 myocardial effect Effects 0.000 description 1
• 208000010125 myocardial infarction Diseases 0.000 description 1
• 230000001338 necrotic effect Effects 0.000 description 1
• 230000030691 negative chemotaxis Effects 0.000 description 1
• 239000013642 negative control Substances 0.000 description 1
• 229960004927 neomycin Drugs 0.000 description 1
• 230000008764 nerve damage Effects 0.000 description 1
• 210000003061 neural cell Anatomy 0.000 description 1
• 230000003988 neural development Effects 0.000 description 1
• 230000004770 neurodegeneration Effects 0.000 description 1
• 230000000626 neurodegenerative effect Effects 0.000 description 1
• 210000004498 neuroglial cell Anatomy 0.000 description 1
• 230000004031 neuronal differentiation Effects 0.000 description 1
• 230000007823 neuropathy Effects 0.000 description 1
• 201000001119 neuropathy Diseases 0.000 description 1
• 239000002858 neurotransmitter agent Substances 0.000 description 1
• 230000007935 neutral effect Effects 0.000 description 1
• 238000011587 new zealand white rabbit Methods 0.000 description 1
• 229910052759 nickel Inorganic materials 0.000 description 1
• 229920002113 octoxynol Polymers 0.000 description 1
• 210000000287 oocyte Anatomy 0.000 description 1
• 230000021368 organ growth Effects 0.000 description 1
• 230000033667 organ regeneration Effects 0.000 description 1
• 230000003204 osmotic effect Effects 0.000 description 1
• 210000002997 osteoclast Anatomy 0.000 description 1
• 208000002865 osteopetrosis Diseases 0.000 description 1
• 201000008968 osteosarcoma Diseases 0.000 description 1
• 238000012261 overproduction Methods 0.000 description 1
• 230000016087 ovulation Effects 0.000 description 1
• YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 description 1
• 229960005489 paracetamol Drugs 0.000 description 1
• 238000012753 partial hepatectomy Methods 0.000 description 1
• 230000008506 pathogenesis Effects 0.000 description 1
• 230000001575 pathological effect Effects 0.000 description 1
• 235000019371 penicillin G benzathine Nutrition 0.000 description 1
• 229940056360 penicillin g Drugs 0.000 description 1
• 230000009984 peri-natal effect Effects 0.000 description 1
• 230000003239 periodontal effect Effects 0.000 description 1
• 210000005259 peripheral blood Anatomy 0.000 description 1
• 239000011886 peripheral blood Substances 0.000 description 1
• 210000001428 peripheral nervous system Anatomy 0.000 description 1
• 208000027232 peripheral nervous system disease Diseases 0.000 description 1
• 208000033808 peripheral neuropathy Diseases 0.000 description 1
• 210000004303 peritoneum Anatomy 0.000 description 1
• 206010034674 peritonitis Diseases 0.000 description 1
• 239000000546 pharmaceutical excipient Substances 0.000 description 1
• 239000012071 phase Substances 0.000 description 1
• 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 239000008363 phosphate buffer Substances 0.000 description 1
• 229910052698 phosphorus Inorganic materials 0.000 description 1
• 239000011574 phosphorus Substances 0.000 description 1
• 238000013310 pig model Methods 0.000 description 1
• 239000000049 pigment Substances 0.000 description 1
• 230000001817 pituitary effect Effects 0.000 description 1
• 210000003635 pituitary gland Anatomy 0.000 description 1
• 239000000902 placebo Substances 0.000 description 1
• 229940068196 placebo Drugs 0.000 description 1
• 230000003169 placental effect Effects 0.000 description 1
• 239000003123 plant toxin Substances 0.000 description 1
• 229940012957 plasmin Drugs 0.000 description 1
• 239000004033 plastic Substances 0.000 description 1
• 229920003023 plastic Polymers 0.000 description 1
• 238000007747 plating Methods 0.000 description 1
• 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
• 229920000573 polyethylene Polymers 0.000 description 1
• 229920001223 polyethylene glycol Polymers 0.000 description 1
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
• 229920002223 polystyrene Polymers 0.000 description 1
• 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
• 230000003389 potentiating effect Effects 0.000 description 1
• 239000000843 powder Substances 0.000 description 1
• 238000001556 precipitation Methods 0.000 description 1
• 230000035935 pregnancy Effects 0.000 description 1
• 238000002360 preparation method Methods 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 230000037452 priming Effects 0.000 description 1
• 230000001023 pro-angiogenic effect Effects 0.000 description 1
• 210000001236 prokaryotic cell Anatomy 0.000 description 1
• 230000035752 proliferative phase Effects 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 230000004952 protein activity Effects 0.000 description 1
• 238000000164 protein isolation Methods 0.000 description 1
• 238000001742 protein purification Methods 0.000 description 1
• 230000012743 protein tagging Effects 0.000 description 1
• 230000017854 proteolysis Effects 0.000 description 1
• 230000001185 psoriatic effect Effects 0.000 description 1
• 229950010131 puromycin Drugs 0.000 description 1
• 239000002510 pyrogen Substances 0.000 description 1
• 229940076788 pyruvate Drugs 0.000 description 1
• 238000011002 quantification Methods 0.000 description 1
• 238000004445 quantitative analysis Methods 0.000 description 1
• 238000011555 rabbit model Methods 0.000 description 1
• 238000000163 radioactive labelling Methods 0.000 description 1
• 238000003127 radioimmunoassay Methods 0.000 description 1
• 238000003156 radioimmunoprecipitation Methods 0.000 description 1
• 238000002708 random mutagenesis Methods 0.000 description 1
• 239000011535 reaction buffer Substances 0.000 description 1
• 238000003753 real-time PCR Methods 0.000 description 1
• 230000008707 rearrangement Effects 0.000 description 1
• 230000006798 recombination Effects 0.000 description 1
• 238000005215 recombination Methods 0.000 description 1
• 238000002278 reconstructive surgery Methods 0.000 description 1
• 230000001172 regenerating effect Effects 0.000 description 1
• 230000008929 regeneration Effects 0.000 description 1
• 238000004153 renaturation Methods 0.000 description 1
• BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
• 239000011347 resin Substances 0.000 description 1
• 229920005989 resin Polymers 0.000 description 1
• 230000003307 reticuloendothelial effect Effects 0.000 description 1
• 210000001525 retina Anatomy 0.000 description 1
• 230000001177 retroviral effect Effects 0.000 description 1
• 230000000250 revascularization Effects 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• 239000002336 ribonucleotide Substances 0.000 description 1
• 125000002652 ribonucleotide group Chemical group 0.000 description 1
• 238000011808 rodent model Methods 0.000 description 1
• 108091008601 sVEGFR Proteins 0.000 description 1
• 239000012266 salt solution Substances 0.000 description 1
• 230000036573 scar formation Effects 0.000 description 1
• 238000013391 scatchard analysis Methods 0.000 description 1
• 238000010845 search algorithm Methods 0.000 description 1
• 238000002805 secondary assay Methods 0.000 description 1
• 238000013207 serial dilution Methods 0.000 description 1
• 229960004509 serum gonadotrophin Drugs 0.000 description 1
• 230000035939 shock Effects 0.000 description 1
• 230000019491 signal transduction Effects 0.000 description 1
• 230000007781 signaling event Effects 0.000 description 1
• 229910052710 silicon Inorganic materials 0.000 description 1
• 239000010703 silicon Substances 0.000 description 1
• 230000012488 skeletal system development Effects 0.000 description 1
• 230000000391 smoking effect Effects 0.000 description 1
• 239000011734 sodium Substances 0.000 description 1
• 238000010532 solid phase synthesis reaction Methods 0.000 description 1
• 239000002904 solvent Substances 0.000 description 1
• 210000001082 somatic cell Anatomy 0.000 description 1
• 238000000527 sonication Methods 0.000 description 1
• 239000000600 sorbitol Substances 0.000 description 1
• 125000006850 spacer group Chemical group 0.000 description 1
• 229940063675 spermine Drugs 0.000 description 1
• 210000000278 spinal cord Anatomy 0.000 description 1
• 238000010186 staining Methods 0.000 description 1
• 238000010561 standard procedure Methods 0.000 description 1
• 210000001562 sternum Anatomy 0.000 description 1
• 238000003756 stirring Methods 0.000 description 1
• 238000003860 storage Methods 0.000 description 1
• 108010018381 streptavidin-binding peptide Proteins 0.000 description 1
• 238000012916 structural analysis Methods 0.000 description 1
• 210000004003 subcutaneous fat Anatomy 0.000 description 1
• 230000001629 suppression Effects 0.000 description 1
• 238000013268 sustained release Methods 0.000 description 1
• 239000012730 sustained-release form Substances 0.000 description 1
• 230000002889 sympathetic effect Effects 0.000 description 1
• 210000000331 sympathetic ganglia Anatomy 0.000 description 1
• NPDBDJFLKKQMCM-UHFFFAOYSA-N tert-butylglycine Chemical compound CC(C)(C)C(N)C(O)=O NPDBDJFLKKQMCM-UHFFFAOYSA-N 0.000 description 1
• 229960000814 tetanus toxoid Drugs 0.000 description 1
• 229960002180 tetracycline Drugs 0.000 description 1
• 229930101283 tetracycline Natural products 0.000 description 1
• 235000019364 tetracycline Nutrition 0.000 description 1
• 150000003522 tetracyclines Chemical class 0.000 description 1
• 229940124597 therapeutic agent Drugs 0.000 description 1
• 238000002560 therapeutic procedure Methods 0.000 description 1
• 239000002562 thickening agent Substances 0.000 description 1
• 108060008226 thioredoxin Proteins 0.000 description 1
• 229940094937 thioredoxin Drugs 0.000 description 1
• 229960004072 thrombin Drugs 0.000 description 1
• 239000003106 tissue adhesive Substances 0.000 description 1
• 229940075469 tissue adhesives Drugs 0.000 description 1
• 239000003104 tissue culture media Substances 0.000 description 1
• 230000025366 tissue development Effects 0.000 description 1
• 230000008467 tissue growth Effects 0.000 description 1
• 230000030968 tissue homeostasis Effects 0.000 description 1
• 230000017423 tissue regeneration Effects 0.000 description 1
• 231100000331 toxic Toxicity 0.000 description 1
• 230000002588 toxic effect Effects 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 238000010361 transduction Methods 0.000 description 1
• 230000026683 transduction Effects 0.000 description 1
• 238000002054 transplantation Methods 0.000 description 1
• 239000012137 tryptone Substances 0.000 description 1
• 201000008827 tuberculosis Diseases 0.000 description 1
• 230000005909 tumor killing Effects 0.000 description 1
• 229910052721 tungsten Inorganic materials 0.000 description 1
• 210000003606 umbilical vein Anatomy 0.000 description 1
• 239000013026 undiluted sample Substances 0.000 description 1
• 241001529453 unidentified herpesvirus Species 0.000 description 1
• 241001430294 unidentified retrovirus Species 0.000 description 1
• 210000000689 upper leg Anatomy 0.000 description 1
• 238000011144 upstream manufacturing Methods 0.000 description 1
• 210000005167 vascular cell Anatomy 0.000 description 1
• 230000006459 vascular development Effects 0.000 description 1
• 208000019553 vascular disease Diseases 0.000 description 1
• 230000006444 vascular growth Effects 0.000 description 1
• 230000008728 vascular permeability Effects 0.000 description 1
• 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
• 230000007998 vessel formation Effects 0.000 description 1
• 108700026220 vif Genes Proteins 0.000 description 1
• 201000001862 viral hepatitis Diseases 0.000 description 1
• 230000006490 viral transcription Effects 0.000 description 1
• 210000002845 virion Anatomy 0.000 description 1
• 239000011782 vitamin Substances 0.000 description 1
• 235000013343 vitamin Nutrition 0.000 description 1
• 229940088594 vitamin Drugs 0.000 description 1
• 229930003231 vitamin Natural products 0.000 description 1
• 230000010388 wound contraction Effects 0.000 description 1
• 239000003357 wound healing promoting agent Substances 0.000 description 1
• 210000002417 xiphoid bone Anatomy 0.000 description 1
• 239000012138 yeast extract Substances 0.000 description 1
• 229910052727 yttrium Inorganic materials 0.000 description 1
• DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1